首页> 外文期刊>Spinal cord: the official journal of the International Medical Society of Paraplegia >Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia.
【24h】

Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia.

机译:逼尿肌肉毒杆菌毒素A注射液对不同程度的脊髓损伤和逼尿肌括约肌功能障碍类型的神经源性逼尿肌过度活跃的治疗作用。

获取原文
获取原文并翻译 | 示例
           

摘要

STUDY DESIGN: The study was designed as a single-arm clinical trial. OBJECTIVES: To investigate the therapeutic effects of detrusor botulinum toxin A (BoNT-A) treatment in patients with different levels of spinal cord injury (SCI) and types of detrusor sphincter dyssynergia (DSD). SETTING: Patients with chronic suprasacral SCI and neurogenic detrusor overactivity (NDO) were treated with 200-U BoNT-A detrusor injection in a tertiary university hospital in Taiwan. METHODS: Outcome assessment of urodynamic parameters and therapeutic satisfaction were performed at 3 and 6 months among patients with different demographics, SCI levels and types of DSD. The treatment outcomes were assessed by changes in Urogenital Distress Inventory 6-item short form (UDI-6), quality of life (QoL) index and detrusor pressure at maximum flow rate (Pdet.Qmax). RESULTS: A total of 38 patients with a mean age of 40.1+/-12.4 years and median duration of SCI of 10.3 years were enrolled. Satisfactory response was reported in 23 (60%) patients. Significant improvements in the UDI-6 and QoL were reported and significant increases of cystometric bladder capacity and post-void residual were noted in overall patients after treatment. Patients with different clinical demographics and urodynamic parameters had similar treatment outcomes and UDI-6 scores. In 11 patients receiving repeat injections of 300 U of BoNT-A after failure of a previous 200 U injection, the treatment outcomes were not significantly different, except that the PdetQmax at 6 months were higher in the group that received 200 U of BoNT-A. CONCLUSION: Patients with different SCI levels or DSD types had similar treatment outcomes after detrusor 200 U BoNT-A injections for NDO.
机译:研究设计:该研究设计为单臂临床试验。目的:探讨逼尿肌肉毒杆菌毒素A(BoNT-A)在不同程度的脊髓损伤(SCI)和逼尿肌括约肌功能障碍(DSD)类型患者中的治疗效果。地点:慢性ter上脊髓神经损伤和神经源性逼尿肌过度活跃(NDO)患者在台湾一家三级大学医院接受200 U BoNT-A逼尿肌注射治疗。方法:对不同人口统计学,SCI水平和DSD类型的患者在3个月和6个月时进行尿动力学参数和治疗满意度的结果评估。通过泌尿生殖器窘迫库存6项简表(UDI-6),生活质量(QoL)指数和逼尿肌压力在最大流速(Pdet.Qmax)的变化来评估治疗结果。结果:共纳入38例患者,平均年龄为40.1 +/- 12.4岁,SCI中位时间为10.3年。据报道有23例(60%)患者反应良好。据报道,治疗后总体患者的UDI-6和QoL均有显着改善,并且膀胱测压膀胱容量和排尿后残留明显增加。具有不同临床人口统计学和尿动力学参数的患者具有相似的治疗效果和UDI-6评分。在先前200 U注射失败后再次注射300 U BoNT-A的11例患者中,治疗结果无显着差异,只是接受200 U BoNT-A的患者在6个月时的PdetQmax更高。结论:不同的SCI水平或DSD类型的患者在逼尿肌200 U BoNT-A注射NDO后具有相似的治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号